Table 1.
Demographic and clinical characteristics of enrolled patients.
| Number (%) | |
|---|---|
| Male gender | 66 (60%) |
| Type of transplant | |
| Heart | 22 (20%) |
| Lung | 26 (23.6%) |
| Kidney | 62 (56.4%) |
| CNIs | |
| Cyclosporine | 22 (20%) |
| Tacrolimus | 83 (75.5%) |
| No | 5 * (4.5%) |
| Anti-proliferative drug | |
| Mycophenolate | 62 (56.4%) |
| Everolimus | 30 (27.3%) |
| Mycophenolate and everolimus | 6 (5.4%) |
| No | 12 (10.9%) |
| Steroid level | |
| Low doses (<5mg/day) | 68 (61.8%) |
| High doses (>5 mg/day) | 3 (2.7%) |
| No | 39 (35.5%) |
| Time after transplant | |
| Less than 1 year | 12 (10.9%) |
| Between 1 and 5 years | 45 (40.9%) |
| More than 5 years | 53 (48.2%) |
| SARS-CoV-2 positivity at T0 | |
| No | 97 (88.2%) |
| Yes | 13 (11.8%) |
Legend CNIs: calcineurin inhibitors; T0: baseline time point.* Three patients received sirolimus in place of CNIs.